{"id":"subject-s-habitual-pga-monotherapy","safety":{"commonSideEffects":[{"rate":"20–50","effect":"Conjunctival hyperemia"},{"rate":"10–30","effect":"Iris pigmentation increase"},{"rate":"5–15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5–10","effect":"Periocular skin pigmentation"},{"rate":"5–15","effect":"Eye irritation/discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prostaglandin analogs are agonists at prostaglandin F (FP) receptors located on the ciliary muscle bundle and trabecular meshwork. Activation of these receptors increases conventional and uveoscleral drainage of aqueous humor from the anterior chamber, thereby lowering intraocular pressure. This mechanism makes them effective first-line agents for glaucoma and ocular hypertension.","oneSentence":"PGA (prostaglandin analog) monotherapy reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:55.874Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Subject's habitual PGA monotherapy","genericName":"Subject's habitual PGA monotherapy","companyName":"Alcon, a Novartis Company","companyId":"alcon-a-novartis-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PGA (prostaglandin analog) monotherapy reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}